Literature DB >> 15147590

The impact of HIV-associated neuropsychological impairment on everyday functioning.

Robert K Heaton1, Thomas D Marcotte, Monica Rivera Mindt, Joseph Sadek, David J Moore, Heather Bentley, J Allen McCutchan, Carla Reicks, Igor Grant.   

Abstract

HIV-1 infection can be associated with neuropsychological (NP) deficits ranging from subtle to severe. The purpose of this study was to evaluate the functional, or "real-world" impact of HIV-associated NP impairment in a group of 267 HIV-infected participants. All participants received comprehensive NP, neuromedical, and standardized functional evaluations that included laboratory measures of shopping, cooking, financial management, medication management and vocational abilities. Compared to NP-normal participants, those with NP impairment performed significantly worse on all laboratory measures of everyday functioning. Multivariate analyses revealed that the NP ability domains of Abstraction/Executive Function, Learning, Attention/Working Memory and Verbal abilities most strongly and consistently predicted failures on the functional battery. Both NP impairment and impairment on the functional battery were significantly associated with subjective experiences of cognitive difficulties, as well as unemployment and increased dependence in activities of daily living; multivariate prediction models that also considered depressed mood and biological measures of disease progression revealed that impairment on the functional battery and depression were the only unique predictors of all three indicators of "real-world" functioning. The current results add to growing evidence concerning the clinical significance of HIV-associated NP impairment. Objective, laboratory based functional measures, such as those used here, may compliment NP testing in future studies directed at understanding the impact on life quality of central nervous system disorders and their treatments. Finally, there is a need for additional research investigating the apparently independent effect of depression on level of everyday functioning in HIV infected persons.

Entities:  

Mesh:

Year:  2004        PMID: 15147590     DOI: 10.1017/S1355617704102130

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  385 in total

1.  Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.

Authors:  Ronald J Ellis; Debralee Rosario; David B Clifford; Justin C McArthur; David Simpson; Terry Alexander; Benjamin B Gelman; Florin Vaida; Ann Collier; Christina M Marra; Beau Ances; J Hampton Atkinson; Robert H Dworkin; Susan Morgello; Igor Grant
Journal:  Arch Neurol       Date:  2010-05

2.  Combined effects of aging and HIV infection on semantic verbal fluency: a view of the cortical hypothesis through the lens of clustering and switching.

Authors:  Jennifer E Iudicello; Steven Paul Woods; Reena Deutsch; Igor Grant
Journal:  J Clin Exp Neuropsychol       Date:  2012-01-31       Impact factor: 2.475

3.  Planning deficits in HIV-associated neurocognitive disorders: component processes, cognitive correlates, and implications for everyday functioning.

Authors:  Jordan E Cattie; Katie Doyle; Erica Weber; Igor Grant; Steven Paul Woods
Journal:  J Clin Exp Neuropsychol       Date:  2012-06-25       Impact factor: 2.475

4.  Relationship of Medication Management Test-Revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIV.

Authors:  Doyle E Patton; Steven Paul Woods; Donald Franklin; Jordan E Cattie; Robert K Heaton; Ann C Collier; Christina Marra; David Clifford; Benjamin Gelman; Justin McArthur; Susan Morgello; David Simpson; J Allen McCutchan; Igor Grant
Journal:  AIDS Behav       Date:  2012-11

5.  Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients.

Authors:  David F Tate; Jared Conley; Robert H Paul; Kathryn Coop; Song Zhang; Wenjin Zhou; David H Laidlaw; Lynn E Taylor; Timothy Flanigan; Bradford Navia; Ronald Cohen; Karen Tashima
Journal:  Brain Imaging Behav       Date:  2010-01-19       Impact factor: 3.978

6.  PrPC, the cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation.

Authors:  Toni K Roberts; Eliseo A Eugenin; Susan Morgello; Janice E Clements; M Christine Zink; Joan W Berman
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

7.  Association of HIV serostatus and metabolic syndrome with neurobehavioral disturbances.

Authors:  Caitlin N Pope; Jessica L Montoya; Elizabeth Vasquez; Josué Pérez-Santiago; Ronald Ellis; J Allen McCutchan; Dilip V Jeste; David J Moore; María J Marquine
Journal:  J Neurovirol       Date:  2020-07-30       Impact factor: 2.643

8.  HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project.

Authors:  N S Ku; Y Lee; J Y Ahn; J E Song; M H Kim; S B Kim; S J Jeong; K-W Hong; E Kim; S H Han; J Y Song; H J Cheong; Y G Song; W J Kim; J M Kim; D M Smith; J Y Choi
Journal:  HIV Med       Date:  2014-02-24       Impact factor: 3.180

9.  Poor Self-efficacy for Healthcare Provider Interactions Among Individuals with HIV-Associated Neurocognitive Disorders.

Authors:  Erin E Morgan; Steven Paul Woods; Jennifer E Iudicello; Igor Grant; Javier Villalobos
Journal:  J Clin Psychol Med Settings       Date:  2019-03

10.  Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

Authors:  Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton
Journal:  Neurology       Date:  2014-05-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.